Trial Profile
Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309,Xiliertinib) in Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Xiliertinib (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 22 Feb 2019 Status changed from recruiting to discontinued.
- 30 Jan 2019 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.
- 30 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.